The Gene Therapy Manufacturing (GTM) facility is a new, 200,000SF two-story facility for viral vector cGMP manufacturing. Phase 1 of the project includes three processing suites for adherent or suspended AAV manufacturing served by a common solution preparation area. The overall project will be BSL2-capable and has a goal of LEED Platinum.